Immune checkpoint inhibitors such as ipilimumab (anti-CTLA-4 antibody) or pembrolizumab (anti-PD-1) have attracted the most attention due to their application to a wide variety of cancer types [82,83,84], with substantial benefit to 20% of treated patients [85,86]. Here, PDCD1 is linked to cancer.